Brief: Effector Therapeutics To Collaborate With Stanford Medicine On Phase 2 Study In Patients With Breast Cancer
April 11 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS TO COLLABORATE WITH STANFORD
MEDICINE ON
INVESTIGATOR-INITIATED RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH
ER+ BREAST CANCER
Source text for Eikon: ID:nGNX28BrLq
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright